Results
|
|
1.
|
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. MedStar authors:
Citation: - Lancet Oncology. 14(9):901-8, 2013 Aug.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
All authors: - Blay JY, Chawla S, Choy E, Ferrari S, Grimer R, Henshaw R, Jacobs I, Kroep J, Qian Y, Reichardt P, Rutkowski P, Schuetze S, Seeger L, Skubitz K, Staddon A, Thomas D
|
|
|
2.
|
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. MedStar authors:
Year: 2019
Citation: - Lancet Oncology. 20(12):1719-1729, 2019 12.
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Blay JY, Chawla S, Choy E, Dai T, Gelderblom H, Grimer RJ, Henshaw R, Jandial D, Le Cesne A, Palmerini E, Reichardt P, Rutkowski P, Schuetze SM, Seeger L, Skubitz K
|
|
|
3.
|
Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. MedStar authors:
Year: 2018
Citation: - World Journal of Surgical Oncology. 16(1):191, 2018 Sep 19.
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Bach BA, Braun A, Chawla S, Choy E, Engellau J, Feng A, Gelderblom H, Grimer R, Henshaw R, Jacobs I, O'Neal M, Reichardt P, Roberts ZJ, Seeger L
|
